Research programme: BACE1 protein inhibitors - The Genetics Company

Drug Profile

Research programme: BACE1 protein inhibitors - The Genetics Company

Alternative Names: BACE inhibitors

Latest Information Update: 07 Jan 2011

Price : $50

At a glance

  • Originator The Genetics Company
  • Class Small molecules
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 07 Jan 2011 Discontinued - Preclinical for Alzheimer's disease in Switzerland (PO)
  • 30 Mar 2006 This programme is still in active development for Alzheimer's disease
  • 30 Mar 2004 Genetics Company and Morphochem have entered into a collaborative agreement for this programme in Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top